TCRX insider trading
NasdaqGM HealthcareTScan Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Company website: www.tscan.com
TCRX insider activity at a glance
FilingIQ tracks 52 insider transactions for TCRX in filings since Jul 22, 2021. The most recent transaction is dated Oct 1, 2026.
Across the full history, 39 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TCRX insider trades is 51.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TCRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TCRX?
- FilingIQ tracks 52 Form 4 insider transactions for TCRX (TScan Therapeutics, Inc.), covering filings from Jul 22, 2021 onwards. 2 of those are dated within the last 90 days.
- Are TCRX insiders net buyers or net sellers?
- Across the full Form 4 history for TCRX, 39 transactions (75%) were open-market purchases and 4 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TCRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TCRX in?
- TScan Therapeutics, Inc. (TCRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $59.75M.
Methodology & sources
Every TCRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.